Olaparib, the first poly(ADP-ribose) polymerase (PARP) inhibitor to be developed, is effective in treating women with breast cancer who have germline pathogenic variants in BRCA1 and/or BRCA2 (gBRCAm), both in the metastatic6,7 and the adjuvant setting8. This evidence concerns the gene BRCA2 and breast carcinoma.